Vaccine after surgery for advanced ovarian cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a cancer vaccine given after surgery to help the immune system better recognize and fight ovarian cancer. It focuses on people with specific tumor genetics and who can start treatment soon after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed stage III epithelial ovarian cancer (or related cancers like primary peritoneal or fallopian-tube cancer).
- You already had upfront surgery, and any remaining tumor is smaller than 1 centimeter after surgery.
- You can start the study treatment within 6 weeks after your debulking surgery.
- Your tumor test shows homologous recombination proficiency (HRP) on an FDA-approved test.
- Your health/strength level is ECOG 0 or 1 (able to do most daily activities).
- Your blood, kidney, and liver function tests are adequate for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a vaccine made from your immune cells (dendritic cell vaccine) given before chemotherapy and surgery. It aims to help your body recognize and fight ovarian cancer more effectively in people whose cancer is advanced and spread.
This trial tests a combination treatment for advanced ovarian cancer that hasn't been treated before. It combines chemotherapy, a personalized vaccine made from your own immune cells, and a drug called pembrolizumab to help your immune system fight the cancer.
This trial tests a new immunotherapy drug (PD-1/CTLA-4 bispecific) combined with two chemotherapy drugs (nab-paclitaxel and carboplatin) given before surgery for advanced ovarian cancer. The goal is to shrink the tumor enough so it can be completely removed during surgery.
This trial tests a personalized vaccine (NeoOVSV) made from your tumor’s unique markers (neoantigens). It’s for women with Stage II or III epithelial ovarian cancer who had successful surgery to remove all visible cancer. The goal is to see if the vaccine is safe and helps your immune system fight any remaining cancer cells.
This trial tests a vaccine called CryptiVax-1001 for people with advanced ovarian cancer who have finished first-line chemotherapy and are in remission, as maintenance therapy. The goal is to see if the vaccine can help keep the cancer from coming back.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tovorilimab) plus bevacizumab and chemotherapy before surgery for advanced ovarian cancer that cannot be removed surgically at first. The goal is to see if this treatment can shrink the tumor enough to allow surgery.
Hear when a new Advanced Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.